title: Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates.
abstract: Recent data published on the prevalence of inhibitors to factor VIII in hemophiliacs on treatment show great variations, with prevalence rates ranging from 3.6 to 14.2%. We have studied the cumulative risk of inhibitor development in a cohort of 62 patients with hemophilia A. All patients were born after 1960, were natives of the Vienna area, had a factor VIII activity of less than 5%, and were treated at least once. Using the method of Cutler and Ederer, the cumulative risk of inhibitor development was found to be 24% at the age of 25 years. Most inhibitors developed between the ages of 3 and 7 years. The current prevalence of F VIII inhibitors in the group of patients studied is 17.5%. It is concluded that prevalence data underestimate the true risk of inhibitor development.
mesh_terms: D000328:Adult; D005169:Factor VIII / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D006467:Hemophilia A / Q000097:blood* / Q000188:drug therapy / Q000401:mortality; D006801:Humans
chemical_list: D005169:Factor VIII